Marksans Pharma Limited has informed the Exchange about Newspaper Publication of Un-Audited financial results for the quarter and nine months ended December 31, 2025
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma Limited has submitted to the NSE a newspaper publication of its unaudited financial results for the quarter and nine months ended December 31, 2025. This is a standard regulatory disclosure required by SEBI's Listing Obligations and Disclosure Requirements (LODR), under which listed companies must publish their quarterly and nine-monthly financial results in at least one English newspaper and one regional language newspaper. The filing itself does not contain the detailed financial figures—it only confirms that the company has complied with the newspaper publication requirement. The full numbers are typically available in the company's standalone and consolidated financial results filed separately.
This is a routine compliance filing and is unlikely to move the stock price on its own. Investors should look at the actual unaudited results for Q3 FY26 (quarter ended December 2025) for any meaningful business insights, as 'un-audited' means the numbers are based on limited review by auditors and are subject to change.